Fingerprint
Dive into the research topics of 'Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT
Lawrence H. Einhorn, Mary J. Brames, Michael C. Heinrich, Christopher L. Corless, Ali Madani
Research output: Contribution to journal › Article › peer-review
93
Scopus
citations